IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Howard-Paul Rounding

USPTO Granted Patents = 19

Average Co-Inventor Count = 8.3

ph-index = 2

Forward Citations = 23(Granted Patents)


Company Filing History:

goldMedal18 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
silverMedal1 out of 2 
 
Bayer Aktiengelsellschaft
 patents

Years Active: 1993-1998

Loading Chart...
19 patents (USPTO):Explore Patents
1. 5721248 - 4-bicyclically substituted dihydropyridines, and their use in medicaments (1998-02-24),
2. 5629320 - 3-quinolyl-substituted dihydropyridines, and their use in medicaments (1997-05-13),
3. 5550245 - 3-quinolyl-substituted dihydropyridines, processes for their preparation (1996-08-27),
4. 5545646 - 4-bicyclically substituted dihydropyridines and their use in medicaments (1996-08-13),
5. 5514803 - 2,6-disubstituted 4-quinolyl-dihydropyridines (1996-05-07),
6. 5508406 - Quinolyl-dihydropyridine esters, processes for their preparation, and (1996-04-16),
7. 5504210 - 3-quinolyl-substituted dihydropyridines and their use in medicaments (1996-04-02),
8. 5504209 - 2-amino-5-cyano-4-quinolydihydropyridine esters, processes for their (1996-04-02),
9. 5502062 - 2-amino-4-quinolyl-dihydropyridines, processes for their preparation, (1996-03-26),
10. 5478937 - Certain cinnoline carboxaldehydes and naphthyridine carboxaldehydes (1995-12-26),
11. 5436342 - Condensed quinolyl-dihydropyridines, processes for their preparation and (1995-07-25),
12. 5434153 - 2-amino-4-heteroaryl-1,4-dihydropyridines and their use in medicaments (1995-07-18),
13. 5432282 - Process for preparing 1,4-dihydro-2-amino-3-carboxy-5-cyano-pyridine (1995-07-11),
14. 5420142 - Certain 3-formyl-1, 4-dihydropyridines and their pharmaceutical (1995-05-30),
15. 5410055 - 3-phenyl-1,7-naphthyridine and cinnoline-5-carboxyaldehyde intermediates (1995-04-25),

Title: Howard-Paul Rounding: Innovator in Cardiovascular Medicaments

Introduction

Howard-Paul Rounding is an accomplished inventor based in Wuppertal, Germany. He holds an impressive portfolio of 19 patents, primarily focused on advancements in the field of medicaments, particularly those targeting cardiovascular diseases. His innovative contributions have made a significant impact on medical therapies and drug development.

Latest Patents

Among his latest patents, Rounding has been instrumental in developing new compounds such as 4-bicyclically substituted dihydropyridines. This invention revolves around novel compounds represented by a specific general formula, where various substituents (R1 to R5) are defined. These compounds have promising applications in developing medicaments for treating cardiovascular diseases. Another noteworthy patent includes 3-quinolyl-substituted dihydropyridines, which are utilized in therapies for cardiovascular conditions, enhancing the effectiveness of treatment options available.

Career Highlights

Throughout his career, Howard-Paul Rounding has collaborated with notable organizations, including Bayer Aktiengesellschaft. His work at this prominent pharmaceutical company underscores his dedication to innovation in the biomedical sector. The advancements he pursued have played a major role in developing effective treatments and improving patient outcomes.

Collaborations

Rounding has worked alongside esteemed colleagues such as Martin Bechem and Siegbert Hebisch. Their collaborative efforts reflect a shared commitment to advancing the pharmaceutical field, leading to significant technological breakthroughs and innovative solutions for cardiovascular health.

Conclusion

Howard-Paul Rounding exemplifies the spirit of innovation in the pharmaceutical industry. With 19 patents to his name, his contributions, especially in the development of medicaments for cardiovascular diseases, showcase his vital role in shaping the future of healthcare. Through his work and collaborations, Rounding continues to inspire advancements that benefit patients globally.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…